Evaluation of the relation of BRAF inhibitor resistance and HIF1 regulation in malignant melanoma cell lines

被引：0
|
作者：
Baskin, Yasemin [1 ]
机构：
[1] Dokuz Eylul Univ, Inst Oncol, Alsancak, Turkey
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2017年 / 76卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
5518
引用
收藏
页码：AB133 / AB133
页数：1
相关论文
共 50 条
  • [1] EVALUATION OF HO-1 INVOLVEMENT IN MELANOMA RESISTANCE TO BRAF INHIBITOR VEMURAFENIB
    Loi, Giulia
    Furfaro, AnnaLisa
    Pronzato, Maria Adelaide
    Pietra, Gabriella
    Nitti, Mariapaola
    POSTGRADUATE MEDICAL JOURNAL, 2018, 94 : A6 - A6
  • [2] Metabolic rewiring in melanoma cell lines that acquired resistance to BRAF inhibitors
    Baenke, F.
    Chaneton, B.
    Smith, M.
    Van den Broek, N.
    Hogan, K.
    Tang, H.
    Viros, A.
    Dhomen, N.
    Gottlieb, E.
    Marais, R.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S55 - S56
  • [3] BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines
    Borst, Andreas
    Haferkamp, Sebastian
    Grimm, Johannes
    Roesch, Manuel
    Zhu, Guannan
    Guo, Sen
    Li, Chunying
    Gao, Tianwen
    Meierjohann, Svenja
    Schrama, David
    Houben, Roland
    CANCER LETTERS, 2017, 404 : 70 - 78
  • [4] Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines
    Tanami, H
    Imoto, I
    Hirasawa, A
    Yuki, Y
    Sonoda, I
    Inoue, J
    Yasui, K
    Misawa-Furihata, A
    Kawakami, Y
    Inazawa, J
    ONCOGENE, 2004, 23 (54) : 8796 - 8804
  • [5] Overcoming resistance to BRAF inhibitors in colon cancer and melanoma cell lines.
    Kelter, Gerhard
    Krumbach, Rebekka
    Giesemann, Torsten
    Vuaroqueaux, Vincent
    Metz, Thomas
    Metcalfe, Thomas
    Fiebig, Heinz-Herbert
    CANCER RESEARCH, 2013, 73 (08)
  • [6] Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines
    Hideaki Tanami
    Issei Imoto
    Akira Hirasawa
    Yasuhiro Yuki
    Itaru Sonoda
    Jun Inoue
    Kohichiro Yasui
    Akiko Misawa-Furihata
    Yutaka Kawakami
    Johji Inazawa
    Oncogene, 2004, 23 : 8796 - 8804
  • [7] Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma
    Montico, Barbara
    Giurato, Giorgio
    Guerrieri, Roberto
    Colizzi, Francesca
    Salvati, Annamaria
    Nassa, Giovanni
    Lamberti, Jessica
    Memoli, Domenico
    Sabatelli, Patrizia
    Comelli, Marina
    Bellazzo, Arianna
    Fejza, Albina
    Camicia, Lucrezia
    Baboci, Lorena
    Dal Bo, Michele
    Covre, Alessia
    Nyman, Tuula A.
    Weisz, Alessandro
    Steffan, Agostino
    Maio, Michele
    Sigalotti, Luca
    Mongiat, Maurizio
    Andreuzzi, Eva
    Fratta, Elisabetta
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2025, 44 (01)
  • [8] Spry1 silencing reduces HIF1α-induced glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma
    Montico, B.
    Giurato, G.
    Guerrieri, R.
    Colizzi, F.
    Salvati, A.
    Nassa, G.
    Lamberti, J.
    Sabatelli, P.
    Comelli, M.
    Bellazzo, A.
    Camicia, L.
    Baboci, L.
    Nyman, T.
    Weisz, A.
    Steffan, A.
    Sigalotti, L.
    Mongiat, M.
    Andreuzzi, E.
    Fratta, E.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S103 - S104
  • [9] Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma
    Duggan, Megan C.
    Stiff, Andrew R.
    Bainazar, Maryam
    Regan, Kelly
    Salavaggione, Gonzalo N. Olaverria
    Maharry, Sophia
    Blachly, James S.
    Krischak, Madison
    Walker, Christopher J.
    Latchana, Nicholas
    Tridandapani, Susheela
    de la Chapelle, Albert
    Eisfeld, Ann-Kathrin
    Carson, William E., III
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (36) : 9629 - 9634
  • [10] Phosphoproteomic analysis of cell-based resistance to BRAF inhibitor therapy in melanoma
    Parker, Robert
    Vella, Laura J.
    Xavier, Dylan
    Amirkhani, Ardeshir
    Parker, Jimmy
    Cebon, Jonathan
    Molloy, Mark P.
    FRONTIERS IN ONCOLOGY, 2015, 5
12345